Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04665765
Title Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors City of Hope Medical Center
Indications

primary mediastinal B-cell lymphoma

diffuse large B-cell lymphoma

B-cell lymphoma

Therapies

Polatuzumab vedotin-piiq

Carboplatin + Etoposide + Ifosfamide + Polatuzumab vedotin-piiq + Rituximab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.